Merck reports 2024 sales at $64.2 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Cancer cases in India estimated to reach 1.57 million in 2025
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Subscribe To Our Newsletter & Stay Updated